CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) has reported robust financial results for the first quarter of fiscal year 2025, posting a 12.8% year-over-year revenue increase to $81.5 billion. Adjusted diluted earnings per share (EPS) rose 13.7% to $3.73, up from $3.28 in the same period last year, while GAAP diluted EPS stood at $2.50 compared to $2.98 in the prior year quarter.
The company has also updated its fiscal year 2025 guidance, raising expected adjusted diluted EPS to a range of $15.25 to $15.55, reflecting confidence in its performance and strategic momentum. Adjusted operating income is now projected to grow between 11.5% and 13.5%, an improvement from the previous guidance range.
“Cencora delivered an excellent start to fiscal 2025 as we focused on advancing our core capabilities and enhancing our value proposition through differentiated services and solutions,” said Robert P. Mauch, President and CEO of Cencora. “We are excited to have closed on our acquisition of Retina Consultants of America on January 2nd, which drives forward our leadership in Specialty and will help us continue to deliver on our strategic imperatives.”
The U.S. Healthcare Solutions segment was a standout performer in the quarter, with revenue rising 13.6% to $74 billion, driven by growth across specialty products and new therapies in the diabetes and weight-loss categories. Meanwhile, International Healthcare Solutions contributed $7.5 billion in revenue, representing a 5.5% increase, supported by gains in European distribution.
Cencora’s acquisition of Retina Consultants of America (RCA) further underscores its commitment to delivering value across the healthcare spectrum. By integrating RCA’s expertise in specialty care, Cencora strengthens its position in the rapidly evolving pharmaceutical landscape.
“Our team members’ dedication to leading with a customer-centric approach and executing on our pharmaceutical-centric strategy enables us to maintain our position as a leading healthcare services provider and drive value for our customers, partners, and shareholders,” Mauch added.
Looking ahead, Cencora’s revised expectations include 8% to 10% revenue growth and significant gains in U.S. Healthcare Solutions’ operating income. The company’s focus on innovative solutions and strategic acquisitions positions it for sustainable growth and strengthened delivery of life-saving therapies to the market, ensuring continued impact on the healthcare sector.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.